Loading
Two years of an olaparib pill after chemotherapy made a large share of women with BRCA-mutated ovarian cancer long-term survivors.
PFS HR 0.30 at the primary analysis (NEJM 2018). At 7 years, 67.0% of olaparib patients were alive versus 46.5% on placebo (HR 0.55; JCO 2023), the first PARP inhibitor trial with a clinically meaningful overall survival gain in the first-line setting and the basis for the 2018 maintenance approval. Roughly half of olaparib patients remained progression-free at 5 years.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
391 randomised.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Olaparib | 260 | - | 0.3 (0.23 to 0.41) | - | link |
| Placebo | 131 | - | ||||
| Overall survival at 7 years | Olaparib | - | 67% | 0.55 (0.4 to 0.76) | - | link |
| Placebo | - | 46.5% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ctDNA-guided duration of PARP maintenance, Kathleen N. Moore, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer.
Shares High-grade serous ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares Platinum-sensitive ovarian cancer, PARP inhibitors, Olaparib, AstraZeneca.
Shares ctDNA-guided duration of PARP maintenance, High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, PARP inhibitors.
Shares PARP inhibitors, PARP, Olaparib, BRCA1 / BRCA2 (HRD).
Shares High-grade serous ovarian cancer, Platinum-sensitive ovarian cancer, PARP inhibitors, PARP.
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/